IP Library Granted Patent US 9,089,568
Granted Patent B2
US 9,089,568 · App. 11/885,687 · Granted Jul 28, 2015

Method of using compatible solutes containing ectoine and/or hydroxyectoine

Inventors: Thomas Schwarz (Mannheim, DE); Georg Lentzen (Herdecke, DE); Jean Krutmann (Wegberg, DE)
Assignee: Bitop AG
A61K31/505A61K31/66A61K31/683A61K31/7032
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,089,568
App. No.
11/885,687
Granted
Jul 28, 2015
Kind
B2
Abstract

The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well.

Claims (7)

1. A method for therapy of chronically inflammable intestinal diseases, comprising administering to a human a compatible solute selected from a group consisting of ectoine, hydroxyectoine and combinations thereof to treat a chronically inflammable intestinal disease.

2. The method of claim 1 , wherein the inflammable intestinal disease is Crohn's disease.

3. The method of claim 1 or 2 wherein administering is performed orally or rectally.

4. The method of claim 1 , wherein the solute is provided in an amount ranging between 1 and 2000 mg of said compatible solute per kg of body weight per day.

5. The method of claim 1 , wherein the solute is in dried or freeze-dried form.

6. The method of claim 1 , wherein the solute is in the form of powder, tablets or capsules.

7. The method of claim 4 , wherein the solute is provided in an amount ranging between 10 to 100 mg of said compatible solute per kg of body weight per day.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Sep 16, 2014
From: BITOP AKTIENGESELLSCHAFT FUR BIOTECHNISCHE OPTIMIERUNG; BITOP AG
To: BITOP AG
Reel/Frame 033753/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2008
From: SCHWARZ, THOMAS; LENTZEN, GEORG; KRUTMANN, JEAN
To: BITOP ATKIENGESELLSCHAFT FUR BIOTECHISCHE OPTIMERUNG
Reel/Frame 020940/0784 →
Priority Claims (1)
DE 10 2005 011 442 · Mar 12, 2005 · national
Continuity (1)
Related Publication 20090060876A1 · Mar 5, 2009